Bristol Myers Squibb (BMS) has yet to announce official presentation plans at the 44 th annual JP Morgan Healthcare Conference, although Karin Shanahan, EVP, chief supply chain and operations officer, ...
In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears ...
The FDA has approved Novo Nordisk’s Wegovy pill to reduce excess body weight, support weight management, and maintain weight ...
AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...
Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...
Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...
Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular ...
In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, ...
Jim Greffet, head of sustainability at Eli Lilly, on establishing ESG as a core business driver—and key complement to ...
Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...
AstraZeneca’s exclusive global licensing deal for Jacobio’s pan-KRAS inhibitor JAB-23E73 underscores a renewed industry push of one of oncology’s most elusive targets. AstraZeneca has announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback